# Castle Biosciences, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Castle Biosciences, Inc). ## Overview Castle Biosciences is a U.S.-based molecular diagnostics company that develops tissue-based tests to help clinicians make treatment and diagnosis decisions in dermatology, gastroenterology, and ophthalmology. Its portfolio is centered on proprietary multi-analyte assays with algorithmic analysis (MAAA), which turn patient tissue samples into clinically actionable risk and treatment information. The company’s commercial focus has expanded from dermatologic cancers into Barrett’s esophagus, uveal melanoma, and atopic dermatitis. Revenue is generated primarily through reimbursement from third-party payors for tests performed in its CLIA-certified laboratories. ## Products & services • DecisionDx-Melanoma • DecisionDx-SCC • MyPath Melanoma • TissueCypher • DecisionDx-UM • AdvanceAD-Tx • IDgenetix (discontinued in May 2025) - **Dermatologic cancer tests** (63%) — Molecular tests used in melanoma and squamous cell carcinoma to help guide diagnosis, staging, and treatment decisions. - **Gastroenterology tests** (25%) — TissueCypher testing for Barrett’s esophagus risk stratification and management support. - **Ophthalmology tests** (8%) — DecisionDx-UM testing for uveal melanoma prognosis and treatment planning. - **Atopic dermatitis test** (4%) — AdvanceAD-Tx, a test intended to guide systemic treatment decisions in moderate-to-severe atopic dermatitis. - DecisionDx-Melanoma - DecisionDx-SCC - MyPath Melanoma - TissueCypher - DecisionDx-UM - AdvanceAD-Tx - IDgenetix (discontinued in May 2025) ## Customers Castle Biosciences sells primarily to clinicians and associated medical staff who order molecular tests to support diagnosis and treatment decisions. Its core customer base is concentrated in U.S. dermatology and gastroenterology, with additional use in ophthalmology and, more recently, atopic dermatitis care. The company’s tests are reimbursed mainly by third-party payors, including Medicare and commercial insurers, so payer coverage is a critical part of customer adoption. Academic and specialty practices are important because they are more likely to adopt evidence-based diagnostic tools and participate in clinical studies that support reimbursement. - **U.S. dermatology practices** (primary) — Buy DecisionDx-Melanoma, DecisionDx-SCC and MyPath Melanoma to improve risk stratification and treatment planning for skin cancer patients. - **Gastroenterology practices** (primary) — Buy TissueCypher to assess Barrett’s esophagus progression risk and guide surveillance or intervention decisions. - **Ophthalmology and ocular oncology centers** (secondary) — Buy DecisionDx-UM to support prognosis and management decisions for uveal melanoma. - **Atopic dermatitis specialists** (emerging) — Buy AdvanceAD-Tx to help guide systemic treatment choices in moderate-to-severe AD. - **Third-party payors** (primary) — Do not buy the tests directly, but their coverage decisions determine whether Castle can convert clinical adoption into reimbursed revenue. - Dermatologists ordering melanoma and SCC tests to refine risk and treatment decisions - Gastroenterologists using TissueCypher for Barrett’s esophagus risk assessment - Ophthalmologists treating uveal melanoma patients with DecisionDx-UM - Clinicians managing moderate-to-severe atopic dermatitis with AdvanceAD-Tx support - Third-party payors that determine reimbursement and coverage access - Patients whose tissue samples are tested, with clinicians as the direct buyers ## Geography Castle Biosciences is operationally centered in the United States, where it generates essentially all of its commercial testing revenue and maintains its sales and medical affairs organization. In 2025 it operated laboratory facilities in Phoenix, Arizona and Pittsburgh, Pennsylvania, both of which are CLIA-certified and CAP-accredited. The company’s laboratories are positioned to serve all 50 states, including jurisdictions with additional licensing requirements such as California, New York, Pennsylvania, Rhode Island, and Maryland. Geography matters mainly through reimbursement rules and state laboratory licensing, rather than through international manufacturing or export exposure. - United States is the core commercial market for all major tests - Laboratories operated in Phoenix, Arizona and Pittsburgh, Pennsylvania - CLIA and CAP accreditation support nationwide testing operations - New York State approval is relevant for certain proprietary tests - State-by-state licensing affects where tests can be marketed and billed - No meaningful international operating footprint is disclosed ## Strategy Castle Biosciences is focused on expanding reimbursement and clinical adoption for its molecular tests, because payor coverage is the main gatekeeper to scalable revenue. It is also investing in direct sales and marketing to educate clinicians and pathologists on the clinical utility and economic value of its products. A second priority is new product development, which supports future growth and helps broaden the portfolio beyond dermatology into adjacent specialty areas. The company also emphasizes operational integration of acquisitions and laboratory efficiency, since its business model depends on converting scientific evidence into reimbursed testing volume at acceptable margins. - **Expand reimbursement coverage** (short-term) — Coverage by Medicare and commercial payors is essential because most revenue comes from reimbursed testing rather than direct consumer sales. - **Increase clinician adoption through sales and medical affairs** (short-term) — The company’s tests require education on clinical utility, so field engagement directly affects test volumes. - **Develop and validate new products** (medium-term) — Pipeline expansion is needed to diversify revenue and create future reimbursable tests in adjacent specialties. - **Integrate acquisitions and scale operations** (medium-term) — Acquired assets can add revenue, but only if integrated efficiently into the existing commercial and laboratory platform. - Expand reimbursement coverage to improve access and revenue conversion - Grow direct sales and marketing to drive clinician adoption - Invest in R&D and clinical studies to support new tests and coverage - Improve laboratory efficiency to protect gross margin - Integrate acquisitions and scale acquired products effectively - Broaden the portfolio beyond dermatology into adjacent specialties ## Risks Castle Biosciences is exposed to reimbursement risk because a large share of revenue depends on a relatively small number of third-party payors and Medicare coverage decisions. The company also faces clinical adoption risk: if clinicians do not view its tests as sufficiently useful or if competing staging criteria and alternative assays gain traction, test volumes can slow. Because the business relies on laboratory operations, it is exposed to regulatory and quality-control requirements tied to CLIA, CAP, and state licensing. More broadly, diagnostics companies face pricing pressure, evidence-generation costs, and the risk that new clinical guidelines or LCD changes can quickly alter demand and realized pricing. - **Payor concentration and reimbursement dependence** [high] — A significant portion of revenue comes from a small number of third-party payors, so coverage or pricing changes can quickly affect revenue. - **Coverage loss for specific tests** [high] — The 2025 loss of Medicare LCD coverage for DecisionDx-SCC reduced realized pricing and revenue contribution. - **Clinical adoption and competitive pressure** [medium] — Demand depends on clinicians preferring Castle’s tests over traditional staging criteria or competing assays. - **Acquisition integration risk** [medium] — Integrating acquired products and operations can distract management and create cost, execution, and retention issues. - **Regulatory and laboratory compliance** [medium] — Testing operations require CLIA, CAP, and state approvals, and noncompliance could restrict operations or billing. - Concentration of revenue among a small number of third-party payors - Medicare LCD or coverage changes can reduce test utilization and pricing - Clinical adoption depends on evidence of utility, validity, and outcomes - Competition from traditional staging criteria and alternative laboratory tests - Regulatory and licensing compliance risk across multiple states - Acquisition integration risk can disrupt operations and increase costs - Need to retain specialized scientific, laboratory, and sales personnel ## Accounting Revenue recognition is a key accounting issue because Castle bills third-party payors and patients for tests performed, and collections depend on reimbursement outcomes that may differ from billed amounts. The company’s revenue can fluctuate materially by quarter as test volumes, payer mix, and coverage decisions change, making period-to-period comparability sensitive to reimbursement timing and realized pricing. Goodwill and intangible assets are also important because the business has grown through acquisitions; these assets must be tested for impairment when operating results or market conditions weaken. Management also relies on estimates for clinical and operational costs, and R&D is expensed as incurred, which means current-period earnings can be affected by study activity and product development intensity. - **Revenue recognition and reimbursement estimates** — Can materially affect reported revenue and accounts receivable - **Quarterly volume and payer-mix volatility** — Creates uneven quarterly revenue and margin trends - **Goodwill and intangible asset impairment** — Potential non-cash charges to earnings - **Acquisition-related amortization** — Reduces reported operating income - **Research and development expense recognition** — Can suppress near-term profitability during pipeline investment cycles - Revenue recognition depends on reimbursement estimates and collections from payors - Quarterly results can swing with test volume, payer mix, and coverage changes - Goodwill and intangible assets require impairment testing after acquisitions - Acquisition accounting affects amortization expense and future earnings - R&D is expensed as incurred, so study activity directly impacts current-period results - Laboratory and payor-related estimates can affect receivables and revenue reserves --- *Last updated: 2026-08-11T04:46:25.521106+00:00*